Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL

[1]  W. Hong,et al.  Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. , 2000, Cancer research.

[2]  K. Bhalla,et al.  Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. , 2000, Blood.

[3]  R. Lotan,et al.  Dual mechanisms of action of the retinoid CD437: nuclear retinoic acid receptor-mediated suppression of squamous differentiation and receptor-independent induction of apoptosis in UMSCC22B human head and neck squamous cell carcinoma cells. , 2000, Molecular pharmacology.

[4]  D. Baltimore,et al.  Signal transduction: A cellular rescue team , 2000, Nature.

[5]  E. Alnemri,et al.  TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. , 2000, Blood.

[6]  J. Blenis,et al.  FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. , 2000, Immunity.

[7]  D. Lawrence,et al.  Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. , 2000, Immunity.

[8]  U. Reichert,et al.  Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases , 2000, Cell Death and Differentiation.

[9]  P. Krammer,et al.  The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. , 2000, Experimental cell research.

[10]  J. Tschopp,et al.  TRAIL receptor-2 signals apoptosis through FADD and caspase-8 , 2000, Nature Cell Biology.

[11]  L. Altucci,et al.  RAR‐independent RXR signaling induces t(15;17) leukemia cell maturation , 1999, The EMBO journal.

[12]  P Chambon,et al.  Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. , 1999, Chemistry & biology.

[13]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[14]  J. Puck,et al.  Inherited Human Caspase 10 Mutations Underlie Defective Lymphocyte and Dendritic Cell Apoptosis in Autoimmune Lymphoproliferative Syndrome Type II , 1999, Cell.

[15]  V. Dixit,et al.  Apoptosis control by death and decoy receptors. , 1999, Current opinion in cell biology.

[16]  S. Minucci,et al.  Retinoid receptors in health and disease: co-regulators and the chromatin connection. , 1999, Seminars in cell & developmental biology.

[17]  W. Zong,et al.  The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis , 1999 .

[18]  S. Gerondakis,et al.  Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. , 1999, Genes & development.

[19]  J C Reed,et al.  IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.

[20]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[21]  R. Gallagher,et al.  The molecular biology of acute promyelocytic leukemia. , 1999, Cancer treatment and research.

[22]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[23]  J. Tschopp,et al.  Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity , 1998, The Journal of experimental medicine.

[24]  Marty W. Mayo,et al.  NF-k B Antiapoptosis : Induction of TRAF 1 and TRAF 2 and c-IAP 1 and c-IAP 2 to Suppress Caspase-8 Activation , 1998 .

[25]  J. Massagué.  TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[26]  M. You,et al.  ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein , 1997, Molecular and cellular biology.

[27]  M. Sporn,et al.  Recent advances in chemoprevention of cancer. , 1997, Science.

[28]  C. Bloomfield,et al.  All-trans-retinoic acid in acute promyelocytic leukemia. , 1997, The New England journal of medicine.

[29]  P. Fenaux,et al.  Differentiation therapy for acute promyelocytic leukemia. , 1997, The New England journal of medicine.

[30]  M. Malim,et al.  Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Schweder,et al.  Human A1, a Bcl-2-related gene, is induced in leukemic cells by cytokines as well as differentiating factors , 1997, Leukemia.

[32]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[33]  Jacek Ostrowski,et al.  Two distinct actions of retinoid-receptor ligands , 1996, Nature.

[34]  R. Lotan.  Retinoids in cancer chemoprevention , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  Philippe Kastner,et al.  Nonsteroid nuclear receptors: What Are genetic studies telling us about their role in real life? , 1995, Cell.

[36]  G. Shipley,et al.  Activation of retinoid X receptors induces apoptosis in HL-60 cell lines , 1995, Molecular and cellular biology.

[37]  M. Lanotte,et al.  Distinct apoptotic responses in maturation sensitive and resistant t(15;17) acute promyelocytic leukemia NB4 cells. 9-cis retinoic acid induces apoptosis independent of maturation and Bcl-2 expression. , 1995, Leukemia.

[38]  M. Sporn,et al.  The Retinoids : biology, chemistry, and medicine , 1994 .

[39]  B. Barres,et al.  Programmed cell death and the control of cell survival: lessons from the nervous system. , 1993, Science.

[40]  S. Lippman,et al.  13-cis-Retinoic Acid Plus Interferon α -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix , 1992 .

[41]  R. Weber,et al.  13-cis-Retinoic Acid and Interferon α -2a: Effective Combination. Therapy for Advanced Squamous Cell Carcinoma of the Skin , 1992 .

[42]  A. Székely,et al.  Letter to the editor: Topical treatment of epidemic Kaposi's sarcoma with all-trans-retinoic acid , 1991 .

[43]  R Berger,et al.  NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). , 1991, Blood.

[44]  A. Székely,et al.  Topical treatment of epidemic Kaposi's sarcoma with all-trans-retinoic acid. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  P. Fenaux,et al.  All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. , 1990, Blood.

[46]  A. Verma,et al.  Inhibition of both stage I and stage II mouse skin tumour promotion by retinoic acid and the dependence of inhibition of tumor promotion on the duration of retinoic acid treatment. , 1987, Cancer research.

[47]  M. Lilly,et al.  Characterization of a new human diploid myeloid leukemia cell line (PLB-985) with granulocytic and monocytic differentiating capacity. , 1987, Blood.

[48]  Najman,et al.  NB 4 , a Maturation Inducible Cell Line With t ( 15 ; 17 ) Marker Isolated From a Human Acute Promyelocytic Leukemia ( M 3 ) , 2022 .